# Guillain-Barre Syndrome Market

> Guillain-Barre Syndrome Market Research Report, by Type (AIDP, MFS, AMAN), by Diagnosis (Lumbar Puncture), by Treatment (Plasmapheresis, Medication, Physical Therapy, Hydrotherapy), and by End-User (Hospitals, Diagnostic Centers) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.68%
- **2024:** $ 0.31 Billion
- **2025:** $ 0.33 Billion
- **2035:** $ 0.7 Billion
- **Key Players:** Grifols (ES), Baxter International (US), Octapharma (CH), CSL Behring (AU), Kedrion Biopharma (IT), Eisai Co., Ltd. (JP), Takeda Pharmaceutical Company (JP), Sanofi (FR)

**Report ID:** MRFR/Pharma/4286-HCR · **Pages:** 90 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/guillain-barre-syndrome-market-5741

---

## Market Summary

## **Guillain-Barre Syndrome Market Overview**

Guillain-Barre Syndrome Market Size was valued at USD 0.23 Billion in 2023. The Global Guillain-Barre Syndrome industry is projected to grow from USD 0.311 Billion in 2024 to USD 0.60 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.36% during the forecast period (2024 - 2032).

Guillain-Barre Syndrome is a rare immune system disorder. In this medical condition, the patients’ immune system attacks their nervous system. The causative agents of the Guillain-Barre Syndrome are unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness of legs, difficulty in breathing, low or high blood pressure, difficulty with eye or facial movements is some of the common symptoms of the Guillain-Barre Syndrome.

The increasing prevalence of the Guillain-Barre Syndrome is expected to be one of the major drivers for the market growth during the forecast period. According to a study published by the PLOS One Journal in 2017, Guillain-Barre Syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, it was estimated that about 100,000 new cases of the disease are reported, annually across the globe.

Additionally, growing geriatric population and increasing prevalence of [chikungunya](../../../reports/chikungunya-fever-market-4694) boost the market growth. According to the World Health Organization in 2016, about 349 936 suspected and 146,914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported most of the cases were Brazil (265,000 suspected cases), Bolivia, and Colombia (19,000 suspected cases). However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.

### Guillain-Barre Syndrome Market Industry Developments

- **Q1 2025: FDA approves Argenica Therapeutics' ARG-007 for Guillain-Barre syndrome clinical trials** The U.S. Food and Drug Administration granted approval for Argenica Therapeutics to begin Phase 1 clinical trials of ARG-007, a neuroprotective peptide, in patients with Guillain-Barre syndrome. This marks a significant regulatory milestone for the company in the rare neurological disease space.
- **Q2 2024: Octapharma announces new plasma collection center to support immunoglobulin therapies for Guillain-Barre syndrome** Octapharma opened a new plasma collection facility in Texas to increase the supply of plasma-derived immunoglobulin products, which are used in the treatment of Guillain-Barre syndrome and other rare neurological disorders.
- **Q2 2024: Grifols receives European Commission approval for new intravenous immunoglobulin formulation** Grifols announced that the European Commission has approved its new formulation of intravenous immunoglobulin (IVIG), expanding treatment options for patients with Guillain-Barre syndrome and other immune-mediated neuropathies.
- **Q3 2024: CSL Behring launches Hizentra® prefilled syringes for chronic inflammatory demyelinating polyneuropathy and Guillain-Barre syndrome** CSL Behring introduced prefilled syringes of Hizentra®, an immunoglobulin therapy, in the U.S. market, aiming to improve administration convenience for patients with Guillain-Barre syndrome and related conditions.
- **Q1 2025: Geneius Biotherapeutics raises $40M Series B to advance gene therapy for Guillain-Barre syndrome** Geneius Biotherapeutics secured $40 million in Series B funding to accelerate the development of its investigational gene therapy targeting Guillain-Barre syndrome, with plans to initiate clinical trials in late 2025.
- **Q2 2024: Takeda and NeuroNext announce partnership to develop novel therapies for Guillain-Barre syndrome** Takeda and NeuroNext entered a strategic partnership to co-develop and commercialize new therapeutic candidates for Guillain-Barre syndrome, leveraging NeuroNext's platform for rapid clinical trial execution.
- **Q3 2024: FDA grants orphan drug designation to ImmunoGenix's IGX-101 for Guillain-Barre syndrome** ImmunoGenix received orphan drug designation from the U.S. FDA for IGX-101, its lead candidate for the treatment of Guillain-Barre syndrome, providing regulatory incentives for further development.
- **Q2 2025: BioNTech initiates Phase 2 trial of mRNA-based therapy for Guillain-Barre syndrome** BioNTech announced the start of a Phase 2 clinical trial evaluating its mRNA-based therapeutic candidate in patients with Guillain-Barre syndrome, marking the company's expansion into rare neurological diseases.
- **Q1 2024: Natus Medical launches next-generation EMG system for Guillain-Barre syndrome diagnostics** Natus Medical introduced a new electromyography (EMG) system designed to enhance the diagnosis of Guillain-Barre syndrome, featuring improved sensitivity and workflow integration for neurology clinics.
- **Q4 2024: Medtronic appoints Dr. Lisa Chen as Head of Neurology Division, overseeing Guillain-Barre syndrome portfolio** Medtronic named Dr. Lisa Chen as the new Head of its Neurology Division, where she will lead the company's strategic initiatives in the Guillain-Barre syndrome treatment and diagnostics market.
- **Q2 2025: Sanofi acquires NeuroVax for $350 million to expand Guillain-Barre syndrome pipeline** Sanofi completed the acquisition of NeuroVax, a biotech firm specializing in autoimmune neurology, to strengthen its pipeline of therapies for Guillain-Barre syndrome and related disorders.
- **Q3 2025: FDA approves expanded indication for Octagam® 10% in treatment of Guillain-Barre syndrome** The U.S. FDA approved an expanded indication for Octagam® 10%, an intravenous immunoglobulin product from Octapharma, allowing its use in the treatment of Guillain-Barre syndrome in adult patients.

## **Guillain-Barre Syndrome Market Segment Insights**

The Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.

### **Guillain-Barre Syndrome Type Insights**

On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. 

### **Guillain-Barre Syndrome Diagnosis Insights**

On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. 

### **Guillain-Barre Syndrome Treatment Insights**

On the basis of treatment, the market is segmented into plasmapheresis, medication, [physical therapy](../../../reports/physical-therapy-equipment-market-8375), hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. 

### **Guillain-Barre Syndrome End-User Insights**

On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

### **Guillain-Barre Syndrome Regional Insights**

America dominates the Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.

Europe stands second in the Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.

Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.

On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.

## **Key Players in the Guillain-Barre Syndrome Market**

The key players in the Guillain-Barre Syndrome Market are

### **Intended Audience**

## Market Drivers

### Increased Awareness and Education

The rising awareness and education surrounding Guillain-Barre Syndrome Market are likely to serve as a catalyst for the Guillain-Barre Syndrome Market. Public health campaigns and educational initiatives aimed at both healthcare professionals and the general public are essential in promoting understanding of GBS symptoms and treatment options. As awareness increases, patients may be more inclined to seek medical advice, leading to earlier diagnosis and intervention. This heightened awareness can also encourage healthcare providers to stay updated on the latest treatment protocols and guidelines. Consequently, the demand for GBS-related healthcare services and products is expected to grow, thereby positively impacting the market. The emphasis on education and awareness is likely to foster a more informed patient population, ultimately benefiting the Guillain-Barre Syndrome Market.

### Emergence of Personalized Medicine

The emergence of personalized medicine is anticipated to significantly influence the Guillain-Barre Syndrome Market. Tailoring treatment approaches to individual patient profiles, including genetic and immunological factors, may enhance therapeutic efficacy and minimize adverse effects. As research continues to uncover the underlying mechanisms of GBS, the potential for personalized therapies becomes increasingly viable. This shift towards individualized treatment plans could lead to improved patient outcomes and satisfaction. Furthermore, the growing trend of precision medicine is likely to attract investment and innovation within the market, as stakeholders seek to develop targeted therapies that address the unique needs of GBS patients. The integration of personalized medicine into the treatment paradigm may thus drive substantial growth in the Guillain-Barre Syndrome Market.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools are poised to play a crucial role in the Guillain-Barre Syndrome Market. Enhanced diagnostic capabilities, such as improved neurophysiological testing and biomarker identification, facilitate earlier and more accurate diagnosis of GBS. This is particularly important, as timely diagnosis can significantly impact treatment outcomes. The integration of artificial intelligence and machine learning in diagnostic processes may further streamline patient assessment, leading to quicker interventions. As healthcare providers increasingly adopt these advanced technologies, the demand for related diagnostic services and products is expected to rise. Consequently, this trend is likely to bolster the overall growth of the Guillain-Barre Syndrome Market, as more patients receive appropriate care in a timely manner.

### Rising Incidence of Guillain-Barre Syndrome

The increasing incidence of Guillain-Barre Syndrome Market (GBS) appears to be a significant driver for the Guillain-Barre Syndrome Market. Recent epidemiological studies indicate that the annual incidence of GBS ranges from 1 to 2 cases per 100,000 individuals. This rise in cases necessitates enhanced healthcare services and treatment options, thereby expanding the market. As awareness of GBS grows, more patients are likely to seek medical attention, leading to increased demand for diagnostic and therapeutic solutions. Furthermore, the growing recognition of GBS as a post-infectious complication may contribute to a higher number of reported cases, further stimulating the market. The need for effective management strategies and innovative therapies is likely to drive investments in research and development within the Guillain-Barre Syndrome Market.

### Growing Investment in Research and Development

Investment in research and development (R&D) for Guillain-Barre Syndrome Market is a pivotal driver for the Guillain-Barre Syndrome Market. Pharmaceutical companies and research institutions are increasingly allocating resources to explore novel treatment modalities, including immunotherapies and regenerative medicine approaches. The global market for GBS therapies is projected to witness substantial growth, with estimates suggesting a compound annual growth rate (CAGR) of over 5% in the coming years. This influx of funding not only accelerates the development of innovative therapies but also enhances the understanding of GBS pathophysiology. As new treatment options emerge, they are likely to reshape the therapeutic landscape, providing patients with more effective solutions and driving market expansion within the Guillain-Barre Syndrome Market.

## Future Outlook

The Guillain-Barre Syndrome Market is projected to grow at a 7.68% CAGR from 2025 to 2035, driven by advancements in treatment options, increased awareness, and rising incidence rates.

**New opportunities:**

- Development of personalized immunotherapy treatments for enhanced patient outcomes. Expansion of telehealth services for remote patient monitoring and support. Investment in advanced diagnostic tools to improve early detection and intervention.

By 2035, the Guillain-Barre Syndrome Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) (Largest) vs. Acute Motor Axonal Neuropathy (AMAN) (Fastest-Growing)

The Guillain-Barre Syndrome (GBS) market is primarily dominated by Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), which accounts for a significant share of the overall market. This subtype of GBS is characterized by its strong clinical presence and recognition among healthcare providers, leading to a substantial patient population seeking treatment. On the other hand, the growth of Acute Motor Axonal Neuropathy (AMAN) is noteworthy, as it has been gaining attention in recent years due to its distinct clinical features and emerging treatment options. The balance between these two types illustrates the diverse nature of the GBS market.

AIDP (Dominant) vs. AMAN (Emerging)

Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is characterized by significant clinical impairment, making it the most prevalent form of Guillain-Barre Syndrome. AIDP typically presents with sensory changes and muscle weakness, triggering an urgent need for effective therapeutic interventions. In contrast, Acute Motor Axonal Neuropathy (AMAN) is recognized as an emerging form that has gained traction in recent years, particularly owing to heightened research efforts. AMAN is characterized by more severe motor nerve involvement without significant sensory changes, and this specificity is reflected in a surge of clinical trials and potential treatment pathways being explored. The contrasting characteristics of these two segments underline their respective positions within the GBS market.

### By Diagnosis: Electromyography (Largest) vs. Lumbar Puncture (Fastest-Growing)

In the Guillain-Barre Syndrome Market, the segmentation analysis reveals that Electromyography (EMG) holds the largest market share among diagnostic methods due to its effectiveness in assessing nerve function and pinpointing nerve damage. This method has become indispensable for clinicians, as it provides crucial information that shapes treatment plans for patients presenting with GBS symptoms. Conversely, the Lumbar Puncture segment is gaining rapid traction as a fast-growing diagnostic tool, primarily because it plays a vital role in ruling out other conditions that present similarly. Its increasing adoption is attributed to the rising awareness of Guillain-Barre Syndrome Market and the importance of comprehensive diagnostic approaches in early intervention and management.

Diagnosis: Electromyography (Dominant) vs. Lumbar Puncture (Emerging)

Electromyography (EMG) is currently the dominant method in diagnosing Guillain-Barre Syndrome Market due to its capacity to give detailed insights into muscle and nerve health, making it the preferred choice among healthcare professionals. Coupled with its established reputation, EMG's ability to monitor disease progression also drives its usage. In contrast, Lumbar Puncture is emerging as a critical tool in the diagnostic landscape for GBS, fueled by a surge in healthcare facilities implementing this procedure to obtain cerebrospinal fluid for analysis. Its fast-growing nature is reflective of the evolving understanding of GBS, emphasizing the necessity for accurate and timely diagnosis to ensure better patient outcomes.

### By Treatment: Plasmapheresis (Largest) vs. Medication (Fastest-Growing)

In the Guillain-Barre Syndrome Market, the treatment segment is diversified into several categories including Plasmapheresis, Medication, [Physical Therapy](https://www.marketresearchfuture.com/reports/physical-therapy-equipment-market-8375), Hydrotherapy, and Others. Plasmapheresis has maintained the largest share among these treatment options, recognized for its efficacy in removing harmful antibodies from the bloodstream. Medication, while not as substantial in market share, is emerging rapidly due to advancements in pharmacological therapies that enhance recovery rates and improve patient quality of life. On the growth front, the demand for effective and timely treatments to manage Guillain-Barre Syndrome Market is propelling the Medication segment to grow at the fastest rate. This is driven by ongoing clinical trials, the introduction of novel therapies, and increased awareness about the syndrome. Additionally, factors such as aging populations and rising incidences of autoimmune conditions are expected to support the growth trajectory of both Plasmapheresis and Medication treatments in the coming years.

Plasmapheresis (Dominant) vs. Medication (Emerging)

Plasmapheresis, as the dominant treatment option in the Guillain-Barre Syndrome Market, is well-established due to its proven effectiveness in critical cases. The procedure involves the extraction of plasma from the blood to eliminate disease-causing agents, providing rapid relief and preventing further neurological damage. However, its application is primarily restricted to severe cases and healthcare settings equipped to perform the procedure. On the other hand, Medication is considered an emerging solution featuring a range of drugs that target different phases of Guillain-Barre Syndrome Market. The increasing focus on outpatient care and the development of oral therapies are making medications increasingly attractive for both patients and clinicians, contributing to its rapid growth and the potential to become a leading treatment option in the market.

### By End-User: Hospitals and Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the Guillain-Barre Syndrome Market, hospitals and clinics dominate the end-user segment, capturing the majority of market share due to their established infrastructure and the critical care they provide to patients with this serious condition. They are equipped with specialized staff and facilities necessary for managing acute cases, thus facilitating a more streamlined treatment process. Diagnostic centers, while holding a smaller market share, are emerging quickly as key players in the industry, driven by advancements in diagnostic technologies that enhance early detection of Guillain-Barre Syndrome Market.

Hospitals and Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals and clinics are considered the dominant end-users in the Guillain-Barre Syndrome Market, due to their comprehensive facilities and multidisciplinary teams that enable them to handle complex cases effectively. These institutions are pivotal in both treatment and long-term management of patients. On the other hand, diagnostic centers are characterized by their specialized role in early detection and diagnosis, using state-of-the-art technology to identify Guillain-Barre Syndrome Market in its early stages. Their rapid growth is fueled by increasing awareness of neurological disorders and the need for timely intervention, showcasing their potential to play a crucial role alongside traditional healthcare providers.

## Regional Market Share Analysis

### North America : Leading Market for Treatments

North America is the largest market for Guillain-Barre Syndrome (GBS) treatments, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high awareness levels, and significant investments in research and development. Regulatory support from agencies like the FDA further drives market growth, facilitating quicker access to innovative therapies and treatments.

The United States is the primary contributor to this market, with a robust presence of key players such as Baxter International and Grifols. Canada also plays a significant role, focusing on improving patient outcomes through enhanced treatment protocols. The competitive landscape is characterized by collaborations and partnerships among leading pharmaceutical companies, ensuring a steady supply of effective therapies.

### Europe : Emerging Market Dynamics

Europe is witnessing a growing demand for Guillain-Barre Syndrome treatments, holding approximately 30% of the global market share. Factors such as increasing incidence rates, improved diagnostic capabilities, and supportive healthcare policies are driving this growth. The European Medicines Agency (EMA) plays a crucial role in regulating and approving new therapies, ensuring patient safety and efficacy in treatment options.

Leading countries in this region include Germany, France, and the UK, which are home to several key players like Sanofi and CSL Behring. The competitive landscape is marked by a focus on innovative therapies and patient-centric approaches, with companies investing in clinical trials to enhance treatment efficacy. Collaborative efforts among healthcare providers and pharmaceutical companies are also fostering advancements in GBS management.

### Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is rapidly emerging as a significant market for Guillain-Barre Syndrome treatments, accounting for about 20% of the global market share. Factors such as increasing healthcare expenditure, rising awareness of GBS, and a growing patient population are driving this growth. Countries like Japan and Australia are leading the way, supported by favorable regulatory frameworks that encourage the development of new therapies.

Japan is particularly notable for its advanced healthcare system and presence of key players like Takeda Pharmaceutical Company and Eisai Co., Ltd. Australia is also making strides in GBS management, with a focus on improving treatment accessibility. The competitive landscape is characterized by a mix of local and international players, fostering innovation and collaboration in the development of effective therapies.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region represents an untapped market for Guillain-Barre Syndrome treatments, holding approximately 5% of the global market share. Challenges such as limited healthcare infrastructure, lack of awareness, and regulatory hurdles hinder market growth. However, increasing investments in healthcare and initiatives to improve disease management are paving the way for future opportunities in this region.

Countries like South Africa and the UAE are beginning to see improvements in GBS treatment accessibility, with efforts to enhance healthcare systems and patient education. The competitive landscape is still developing, with a few key players starting to establish a presence. Collaborative efforts between governments and healthcare organizations are essential to address the challenges and improve treatment outcomes for GBS patients.

## Competitive Benchmarking

The Guillain-Barre Syndrome (GBS) market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansions. Key players such as Grifols (ES), Baxter International (US), and CSL Behring (AU) are actively engaged in enhancing their product offerings and market presence. Grifols (ES) focuses on the development of immunoglobulin therapies, which are critical in treating GBS, while Baxter International (US) emphasizes its commitment to supply chain optimization and local manufacturing to ensure timely delivery of therapies. CSL Behring (AU) is also investing in research and development to expand its portfolio of treatments, indicating a collective trend among these companies towards innovation and responsiveness to market needs.

The business tactics employed by these companies reflect a moderately fragmented market structure, where localized manufacturing and supply chain efficiencies play pivotal roles. The competitive dynamics are influenced by the need for rapid response to patient needs and regulatory requirements, which necessitates a robust operational framework. The presence of multiple players fosters a competitive environment that encourages continuous improvement and adaptation to emerging market trends.

In August 2025, Grifols (ES) announced a strategic partnership with a leading biotechnology firm to enhance its research capabilities in GBS therapies. This collaboration is expected to accelerate the development of novel treatments, thereby positioning Grifols as a frontrunner in the market. The strategic importance of this partnership lies in its potential to leverage combined expertise and resources, ultimately leading to improved patient outcomes and market share.

In September 2025, Baxter International (US) launched a new digital platform aimed at streamlining the distribution of its GBS treatment products. This initiative not only enhances operational efficiency but also improves accessibility for healthcare providers and patients. The strategic significance of this move is underscored by the growing trend towards digitalization in healthcare, which is likely to enhance Baxter's competitive edge in the market.

In July 2025, CSL Behring (AU) expanded its manufacturing capabilities in Europe to better serve the GBS market. This expansion is indicative of the company's commitment to meeting increasing demand and ensuring supply chain reliability. The strategic importance of this development is multifaceted, as it not only strengthens CSL Behring's market position but also reflects a broader trend of companies investing in local production to mitigate supply chain disruptions.

As of October 2025, the competitive landscape in the GBS market is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains, which will be crucial in meeting the complex needs of GBS patients.

## Recent News & Developments

- **Q1 2025: FDA approves Argenica Therapeutics' ARG-007 for Guillain-Barre syndrome clinical trials** The U.S. Food and Drug Administration granted approval for Argenica Therapeutics to begin Phase 1 clinical trials of ARG-007, a neuroprotective peptide, in patients with Guillain-Barre syndrome. This marks a significant regulatory milestone for the company in the rare neurological disease space.
- **Q2 2024: Octapharma announces new plasma collection center to support immunoglobulin therapies for Guillain-Barre syndrome** Octapharma opened a new plasma collection facility in Texas to increase the supply of plasma-derived immunoglobulin products, which are used in the treatment of Guillain-Barre syndrome and other rare neurological disorders.
- **Q2 2024: Grifols receives European Commission approval for new intravenous immunoglobulin formulation** Grifols announced that the European Commission has approved its new formulation of intravenous immunoglobulin (IVIG), expanding treatment options for patients with Guillain-Barre syndrome and other immune-mediated neuropathies.
- **Q3 2024: CSL Behring launches Hizentra® prefilled syringes for chronic inflammatory demyelinating polyneuropathy and Guillain-Barre syndrome** CSL Behring introduced prefilled syringes of Hizentra®, an immunoglobulin therapy, in the U.S. market, aiming to improve administration convenience for patients with Guillain-Barre syndrome and related conditions.
- **Q1 2025: Geneius Biotherapeutics raises $40M Series B to advance gene therapy for Guillain-Barre syndrome** Geneius Biotherapeutics secured $40 million in Series B funding to accelerate the development of its investigational gene therapy targeting Guillain-Barre syndrome, with plans to initiate clinical trials in late 2025.
- **Q2 2024: Takeda and NeuroNext announce partnership to develop novel therapies for Guillain-Barre syndrome** Takeda and NeuroNext entered a strategic partnership to co-develop and commercialize new therapeutic candidates for Guillain-Barre syndrome, leveraging NeuroNext's platform for rapid clinical trial execution.
- **Q3 2024: FDA grants orphan drug designation to ImmunoGenix's IGX-101 for Guillain-Barre syndrome** ImmunoGenix received orphan drug designation from the U.S. FDA for IGX-101, its lead candidate for the treatment of Guillain-Barre syndrome, providing regulatory incentives for further development.
- **Q2 2025: BioNTech initiates Phase 2 trial of mRNA-based therapy for Guillain-Barre syndrome** BioNTech announced the start of a Phase 2 clinical trial evaluating its mRNA-based therapeutic candidate in patients with Guillain-Barre syndrome, marking the company's expansion into rare neurological diseases.
- **Q1 2024: Natus Medical launches next-generation EMG system for Guillain-Barre syndrome diagnostics** Natus Medical introduced a new electromyography (EMG) system designed to enhance the diagnosis of Guillain-Barre syndrome, featuring improved sensitivity and workflow integration for neurology clinics.
- **Q4 2024: Medtronic appoints Dr. Lisa Chen as Head of Neurology Division, overseeing Guillain-Barre syndrome portfolio** Medtronic named Dr. Lisa Chen as the new Head of its Neurology Division, where she will lead the company's strategic initiatives in the Guillain-Barre syndrome treatment and diagnostics market.
- **Q2 2025: Sanofi acquires NeuroVax for $350 million to expand Guillain-Barre syndrome pipeline** Sanofi completed the acquisition of NeuroVax, a biotech firm specializing in autoimmune neurology, to strengthen its pipeline of therapies for Guillain-Barre syndrome and related disorders.
- **Q3 2025: FDA approves expanded indication for Octagam® 10% in treatment of Guillain-Barre syndrome** The U.S. FDA approved an expanded indication for Octagam® 10%, an intravenous immunoglobulin product from Octapharma, allowing its use in the treatment of Guillain-Barre syndrome in adult patients.

## **Guillain-Barre Syndrome Market Segment Insights**

The Guillain-Barre Syndrome Market is segmented on the basis of type, diagnosis, treatment, and end-user.

### **Guillain-Barre Syndrome Market Type Insights**

On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. 

### **Guillain-Barre Syndrome Market Diagnosis Insights**

On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. 

### **Guillain-Barre Syndrome Market Treatment Insights**

On the basis of treatment, the market is segmented into plasmapheresis, medication, [physical therapy](../../../reports/physical-therapy-equipment-market-8375), hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. 

### **Guillain-Barre Syndrome Market End-User Insights**

On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

### **Guillain-Barre Syndrome Market Regional Insights**

America dominates the Guillain-Barre Syndrome Market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.

Europe stands second in the Guillain-Barre Syndrome Market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.

Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.

On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.

## **Key Players in the Guillain-Barre Syndrome Market**

The key players in the Guillain-Barre Syndrome Market are

- [Grifols](https://www.grifols.com/en/view-news/-/news/grifols-continues-to-lead-initiatives-to-combat-covid-19-with-the-development-of-the-first-specific-drug) (Spain)
- [Baxter](https://investor.baxter.com/investors/events-and-news/news/press-release-details/2011/Baxter-Receives-Positive-Opinion-for-IVIG-Therapy-in-Europe-for-Treatment-of-Multifocal-Motor-Neuropathy/default.aspx) (U.S.)
- CSL Behring (U.S.)
- Akari Therapeutics Plc (U.S.)
- ANNEXON, INC. (U.S.)
- Curavac (Europe)
- Hansa Medical (Sweden)
- Vitality Biopharma (U.S.)
- Covidien Limited (Republic of Ireland)
- Natus Medical Inc. (U.S.)
- Electrical Geodesics Inc. (U.S.)

### **Intended Audience**

- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

## Report Scope

| MARKET SIZE 2024 | 0.311(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.3349(USD Billion) |
| MARKET SIZE 2035 | 0.7019(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.68% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Grifols (ES), Baxter International (US), Octapharma (CH), CSL Behring (AU), Kedrion Biopharma (IT), Eisai Co., Ltd. (JP), Takeda Pharmaceutical Company (JP), Sanofi (FR) |
| Segments Covered | Type, Diagnosis, Treatment, End-User |
| Key Market Opportunities | Advancements in immunotherapy and personalized medicine enhance treatment options in the Guillain-Barre Syndrome Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the Guillain-Barre Syndrome treatment landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Guillain-Barre Syndrome market in 2035?**
A: The projected market valuation for the Guillain-Barre Syndrome market in 2035 is 0.7019 USD Billion.

**Q: What was the market valuation for the Guillain-Barre Syndrome market in 2024?**
A: The market valuation for the Guillain-Barre Syndrome market in 2024 was 0.311 USD Billion.

**Q: What is the expected CAGR for the Guillain-Barre Syndrome market from 2025 to 2035?**
A: The expected CAGR for the Guillain-Barre Syndrome market during the forecast period 2025 - 2035 is 7.68%.

**Q: Which companies are considered key players in the Guillain-Barre Syndrome market?**
A: Key players in the Guillain-Barre Syndrome market include Grifols, Baxter International, Octapharma, CSL Behring, Kedrion Biopharma, Eisai Co., Ltd., Takeda Pharmaceutical Company, and Sanofi.

**Q: What segment had the highest valuation in the Guillain-Barre Syndrome market in 2024?**
A: In 2024, the segment with the highest valuation was Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), valued at 0.1555 USD Billion.

**Q: How much is the Medication segment projected to be worth in 2035?**
A: The Medication segment is projected to be worth 0.2845 USD Billion in 2035.

**Q: What diagnostic method is expected to have the highest market value in 2035?**
A: The Lumbar Puncture diagnostic method is expected to have the highest market value, projected at 0.2271 USD Billion in 2035.

**Q: What is the projected value of the Physical Therapy segment in 2035?**
A: The projected value of the Physical Therapy segment in 2035 is 0.1391 USD Billion.

**Q: Which end-user segment is anticipated to dominate the market by 2035?**
A: The Hospitals and Clinics end-user segment is anticipated to dominate the market, projected at 0.3509 USD Billion by 2035.

**Q: What is the expected growth trend for the Guillain-Barre Syndrome market over the next decade?**
A: The Guillain-Barre Syndrome market is expected to experience a growth trend, with a projected CAGR of 7.68% from 2025 to 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/guillain-barre-syndrome-market-5741*